Man Group’s Lyell Immunopharma LYEL Stock Holding History

Man Group’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,710	Closed	-$105K	–	2204
2023 Q4	$105K	Buy	+2,710	New	+$97.6K	﹤0.01%	1978

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's LYEL Position: Q1 2024 in Review

Man Group sold out of Lyell Immunopharma (LYEL) in Q1 2024, closing a stake of 2,710 shares — an estimated $105K sold.

Man Group first reported a position in LYEL in Q4 2023 and held it in 1 quarter. The position peaked at $105K in Q4 2023. 127 funds tracked by Wall St. Rank hold LYEL as of Q1 2024.

Man Group reported no remaining Lyell Immunopharma position as of Q1 2024 after selling out during the quarter.
Man Group sold 2,710 Lyell Immunopharma shares in Q1 2024, an estimated $105K.
Man Group first reported a position in Lyell Immunopharma in Q4 2023 and held it in 1 quarter.
Man Group's Lyell Immunopharma position peaked at $105K in Q4 2023.
127 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.